Does tacrolimus have any positive impact on outcome of post-transplant breast cancer patients?
- 314 Downloads
I wish to congratulate Jeong and colleagues for their article  in which the characteristics and prognosis of post-transplant breast cancer (PTBC) patients receiving immunosuppressants and general breast cancer patients were compared. They reported that subtype and prognosis of breast cancer were comparable with that in the general cohort and immunosuppressants do not adversely affect breast cancer prognosis. In this study, 24 were diagnosed with PTBC. Of the 24 PTBC cohort, 12 received mammalian target of rapamycin (mTOR) inhibitor—tacrolimus as immunosuppressive agent. Results of both the TAMRAD and BOLERO-2 studies showed that mTOR inhibition in combination with endocrine therapy improved progression-free survival for hormone receptor-positive metastatic breast cancer patients . For this reason, it would be interesting to compare the outcome of hormone receptor-positive PTBC patients who received endocrine treatment and tacrolimus with hormone receptor-positive patients in general cohort.
The author has not received any grants.
Compliance with ethical standards
Conflict of interest
I have no conflict of interest to declare.
My manuscript complies with the Ethical Rules applicable for this journal.
Research involving human and animal participants
This article does not contain any studies with human participants or animals performed by the author.